These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 631415)

  • 21. Antihypertensive effect of oxprenolol and chlorthalidone in fixed combination, given once daily.
    Buoninconti R; Motolese M; Rubegni M
    J Int Med Res; 1979; 7(6):519-23. PubMed ID: 391625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once daily dosage beta-blockade: antihypertensive efficacy of slow release oxprenolol as related to renin and age.
    Bühler FR; Lütold BE; Küng M; Koller FJ
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):37-43. PubMed ID: 1071402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of long term oxprenolol and chlorthalidone singly and in combination in hypertensive blacks.
    Obel AO
    Jpn Heart J; 1990 Mar; 31(2):183-92. PubMed ID: 2192098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.
    Bradbrook ID; Babiker M; Crome P; Gillies HC; Morrison PJ; Rogers HJ; Shotton P
    Br J Clin Pharmacol; 1986 Apr; 21(4):371-6. PubMed ID: 3707811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Slow-release oxprenolol and chlortalidone administered once daily in essential hypertension].
    Rossi A; Ziacchi V; Fracalossi C; Marino A; Lomanto B
    Minerva Cardioangiol; 1984 Dec; 32(12):949-62. PubMed ID: 6531101
    [No Abstract]   [Full Text] [Related]  

  • 28. Oxprenolol slow-release with cyclopenthiazide-KCl compared with methyldopa in the treatment of essential hypertension. A multicentre general practice trial.
    Levenstein JH
    S Afr Med J; 1978 Nov; 54(21):860-4. PubMed ID: 371021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study.
    Levenstein JH
    S Afr Med J; 1981 Jun; 59(25):893-9. PubMed ID: 7015537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
    Ravid M; Lang R; Jutrin I
    Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial.
    Materson BJ; Friedman BA; Hla KM; Neidorf BS; Gray JM; Glazer N; Gross S
    Drug Intell Clin Pharm; 1983 Jan; 17(1):51-4. PubMed ID: 6337801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K.
    Ebbutt AF; Elsdon-Dew RW
    J Int Med Res; 1979; 7(6):524-7. PubMed ID: 520655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Continuous 24-hour registration of intra-arterial pressure in basal states and during therapy with a fixed slow-release oxprenolol-chlorthalidone combination, administered once a day].
    Fariello R; Alicandri C; Boni E; Montini E; Zaninelli A; Agabiti-Rosei E; Motolese M; Muiesan G
    G Ital Cardiol; 1984 Feb; 14(2):121-6. PubMed ID: 6714549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive effectiveness of oxprenolol administered twice daily.
    Materson BJ; Oster JR; Michael UF; Perez-Stable EC
    Clin Pharmacol Ther; 1976 Mar; 19(3):325-32. PubMed ID: 770050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "24-hour blood pressure control" with sustained release oxprenolol 160mg plus cyclopenthiazide 0.25mg (Trasidrex) in general practice.
    Forrest WA; Bridgman KM; Ebbutt AF
    Br J Clin Pract; 1983; 37(11-12):385-8. PubMed ID: 6367794
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. Echocardiographic study.
    Bertoni T; Alberti D; Peloso A; Francucci BM; De Ambroggi L
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):148-52. PubMed ID: 2970442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of essential hypertension with oxprenolol and chlorthalidone in a fixed combination.
    Karachalios GN
    Int J Clin Pharmacol Res; 1983; 3(3):153-6. PubMed ID: 6679518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-hypertensive efficacy of combined alpha- and beta-adrenoreceptor blockade with phentolamine-oxprenolol or with labetalol (AH 5158).
    Johnson BF; LaBrooy J; Munro-Faure AD
    Clin Sci Mol Med Suppl; 1976 Dec; 3():505s-507s. PubMed ID: 799558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical responses to oxprenolol in the elderly.
    Ellis RA
    Am J Cardiol; 1983 Nov; 52(9):62D-65D. PubMed ID: 6356866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.